




Epidemiology and clinical presentation of dogs infected with sarcoptic 
mange 
Raluca MÎNDRU1, Constantin ROMAN1, Andrei C. LUPU1, Gabriela V. MARTINESCU1, 
Larisa M. IVĂNESCU1, Dumitru M. ACATRINEI1, Ilie BODALE2, Jacques GUILLOT3, 
Liviu D. MIRON1 
1. University of Agricultural Sciences and Veterinary Medicine ”Ion Ionescu de la Brad” Iași, 
Faculty of Veterinary Medicine, Department of Parasitology and Parasitic Diseases, 
Aleea M. Sadoveanu, nr. 8, Email address raluk_1990@yahoo.com 
2. University of Agricultural Sciences and Veterinary Medicine ”Ion Ionescu de la Brad” Iași, 
Faculty of Horticulture, Department of Sciences 
3. Ecole Nationale Vétérinaire d'Alfort, Unité de Parasitologie, Mycologie, Dermatologie 
DSBP, BioPôle d'Alfort, France 
 
Abstract 
Sarcoptic mange in dog is a common parasitic dermatitis, especially in non-controlled, stray dogs that 
develop evocative clinical signs. The present study includes 48 dogs, with different backgrounds, both 
privately owned and dogs from shelters. We searched for predisposing factors for contacting sarcoptic 
mange, such as: age, sex, breed, source of contamination. Their age ranged from 1.15 months to 12 years 
(with more than a half being under 1 year old), they were mostly common or cross-breed dogs, and the sex 
ratio was almost equal, with 25 females and 23 males. All dogs were naturally infected with Sarcoptes 
scabiei, as confirmed by identification on the microscope of skin scrapings from different body areas. 
Furthermore, we aimed to have a general idea concerning the severity of infection with Sarcoptes scabiei in 
the dogs we studied. The dogs received a clinical score based on the evaluation of typical signs that appear 
in sarcoptic mange such as alopecia, erythema, scales/crusts and the extent of mange on the cutaneous 
surface on different body parts (head, trunk, legs, tail). The most affected body part was the head, followed 
by the trunk and the most scored sign was the extent of affected skin and alopecia. The treatment consisted 
in the administration of either afoxolaner (Nexgard®), twice at a monthly interval (2.7-6.9 mg/kg), either 
sarolaner (Simparica®), twice at a monthly interval (2-4 mg/kg), or doramectin (Dectomax®) 0.2 mg/kg, 
twice at 14 days interval. 
Key words: clinical signs of mange, predisposing factors of mange, Sarcoptes scabiei 
 
Introduction 
Canine sarcoptic mange is an unseasonal, highly contagious and pruritic dermatitis that 
affects domestic and wild canids, and rarely cats (Scott et al., 1995). 
The disease is caused by the burrowing mite Sarcoptes scabiei var. canis. The zoonotic 
aspect is quite important, as direct contact with an infected dog can cause a mild irritation of the 
skin in humans, accompanied by pruritus. However, the disease is self-limiting, which means that 
the mites cannot reproduce in human skin and would eventually die (Mounsey and Walton, 2001). 
Mange is often a problem in shelters or in big communities of animals, where dogs are closely in 
contact with each other and disinfection is not done properly. However, there are cases of infection 
with S. scabiei mites in privately-owned dogs, the contamination occurring by direct contact with 
an infected animal (dog or fox) or through fomites. Young dogs, of less than 2 years, are usually 
more affected, with no predisposition of sex (Bourdeau et al., 2004; Feather et al., 2010). 
The clinical presentation of scabies in dogs includes intense pruritus, alopecia, erythema, 
yellowish crusts and papules on the skin. The typical affected regions of the body are the periocular 






The diagnosis is established based on the microscopic identification of adults, larvae, eggs 
or feces of S. scabiei in skin scrapings from multiple areas that present lesions. However, the 
number of mites found is usually very low, which makes diagnosis difficult (Griffin, 1993). 
Treatment for sarcoptic mange in dogs includes the following molecules, authorized in the 
European Union: imidacloprid/moxidectin (spot-on), selamectin (spot-on), sarolaner (tablet) and 
the newly approved afoxolaner and afoxolaner/milbemycin oxime (tablet). However, other 
systemic molecules can be used off-label, as proven effective against S. scabiei, such as: ivermectin 
(Paradis, 1998), doramectin, milbemycin oxime (Miller et al., 1996), moxidectin (Wagner et al., 
2000) or fluralaner (Romero et al., 2016; Taenzler et al., 2016). 
The aim of our study was to identify the predisposing factors that make some dogs contact 
the disease more easily, as little is known regarding this topic. These factors include age, sex, breed, 
source of contamination with mange, background of the animal. Furthermore, we aimed to make a 
general evaluation of the degree of intensity of the clinical signs caused by sarcoptic mange in 
dogs. 
 
Materials and methods 
The dogs included in the study presented typical clinical signs of mange (pruritus, crusts, 
alopecia), confirmed by positive skin scrapings (identification of S. scabiei). 
The history of the dog was recorded through a questionnaire addressed to the owner. The 
fields included the presentation of the animal, the breed, the sex, the age, if there were other in 
contact animals (especially dogs), if cutaneous problems appeared in the owner or in other 
members of the house. 
For the direct examination and identification of S. scabiei, samples were collected through 
deep skin scrapings from different body sites presenting lesions evocative of sarcoptic mange 
(alopecia, crusts and scales). An area of approximately 4 cm2, from different body sites was scraped 
with a scalpel until capillary bleeding appeared. The skin scrapings were then put on a slide with 
lactophenol or mineral oil, macerated and spread in the liquid, then covered with a coverslip and 
examined with the 10X objective of the microscope. 
Adults and nymphs of S. scabiei were identified based on morphological aspects (size, oval 
shaped, short legs, dorsal part with thorns and spines and ventral part with epimers). Larvae were 
identified based on their number of 6 legs and resemblance to adult mites, and eggs were identified 
by size and shape. 
As far as the clinical examination is concerned, at the beginning of the study, all dogs 
received a general health evaluation. 
Furthermore, for the dermatological examination, an original clinical score adapted for 
dogs, but initially designed for pigs infected with S.scabiei was used (Bernigaud et al., 2016). The 
score included the evaluation of the skin areas affected by mange, alopecia degree, intensity of the 
skin erythema and crusting/scales intensity, on different parts of the body (head, trunk, legs and 
tail). The grades per sign were from 0 to 4, with 4 being the most severe, which resulted in a total 
clinical score between 0 and 60. The score was assessed at the first visit. 
The treatment protocol for the dogs included in this study was made with three specific 
acaricid product demonstrated to be efficient against S. scabiei infection. 
Three acaricid molecules were used: afoxolaner (Nexgard®) administered twice at a 
monthly interval (2.7-6.9 mg/kg), or sarolaner (Simparica®) administered twice at a monthly 
interval (2-4 mg/kg), or doramectin (Dectomax®) 0.2 mg/kg administered twice at 14 days interval. 





sarcoptic mange in dogs at that period of time, was sarolaner (Simparica®). The owners were 
informed and agreed to the treatment protocol. The follow up of the dog was scheduled every two 
weeks for the doramectin treated dogs, over a period of one month. For the dogs treated with 
sarolaner or afoxolaner it was scheduled every month for a period of two months. 
 
Results 
This study included 48 dogs (A1-A48), which were examined between 2016 and 2019-27 
were examined during consultation in the Parasitology Clinic of the Faculty of Veterinary Medicine 
of Iași and 21 were examined in private households (14 from Vaslui County) or shelters (7). 
They were mostly common or crossbreed dogs (n=39, 81.25%). Few were from the 
following breeds: Boxer (a mother with her 7 puppies), Bull Terrier (1) and Poodle (1). Their age 
ranged between 1.15 month old and 12 years old, with more than half of them (n=28, 58.33%) 
being under 1 year. Finally, the individuals included represented almost equally both sexes, with 
23 males (48% of the total) and 25 females (52% of the total). 
Concerning the history of the dogs, a great number were stray dogs which were in shelters 
or in foster families (n=21, 43.7%), resulting in the fact that the information we had about them 
was limited. We also studied households that had multiple dogs. 
Regarding the source of scabies, it is largely unknown, since a big number of animals were 
former stray dogs. However, in one case, the owner noticed the lesions on the dog’s skin soon after 
a fox with skin lesions had wandered through their yard. 
We also included 7 dogs (14.5% from the total number) that belonged to the shelters. 
The zoonotic transmission of the disease was reported in only one dog, that had the most 
severe lesions and that was hospitalized in our clinic. The infection occurred in one of the clinical 
staff that manipulated the dog during the treatment, and manifested through pruritus and papules 
on the arm and forearm. 
The skin scrapings examined through direct examination were positive for S. scabiei 
adults, larvae or eggs. However, we observed very few parasitic elements in the samples collected. 
The clinical sign observed more frequently was the extent of scabies affected skin, followed 
closely by alopecia (Figure 1), then scales/crusts (Figure 2&3) and finally, the least 







Figure 1- Clinical picture-alopecia in dog Figure 2- Clinical picture-scales in dog 
 
Figure 3- Clinical picture-thick crusts in dog Figure 4-Clinical picture- extent of scabies 
affected skin and erythema 
 
 
The clinical scores of the 48 dogs varied between a minimum of 4 and a maximum of 58, 
taking into consideration that the maximum score which could be obtained was 60 (Figure 5). This 
is a clear illustration of the fact that the dogs we studied had from very discrete lesions to serious, 






Figure 5- Clinical score at consultation 
 
Another representation of the clinical score range is showed in Figure 6. We can observe 
that the males studied reached a higher clinical score, mainly because of the dog A10. Also, the 
females start from a lower score than the males. 
 
 






















Figure 7 - Different clinical presentation of sarcoptic mange: left severely affected dog, right 
mild lesions on the ears 
 
Regarding correct administration and follow-up of the treatment, only 16 dogs respected 
the requirements stated 
 
Discussion 
The number of dogs included in this study was 48, which is similar to the epidemiological 
study Feather et al. conducted in dogs in 2010, where they investigated retrospectively 42 dogs. 
Regarding the diagnosis of S. scabiei infection, the confirmation resides in the positivity 
of the skin scraping, which shows different life stages of the mite, or its feces. However, the 
problem resides in the low number of mites generally observed in the samples (Miller et al., 2012). 
Different types of PCR tests can be performed to confirm the mite infection (Angelone-Alasaad et 
al., 2015), but their cost are high. 
The techniques used to evaluate the clinical score, were similar to those used in other 
studies, and included evaluation of alopecia, inflammation (erythema), crusts and scales. The score 
we used in the study had, however, an original feature in evaluating the extent of the scabies 
affected skin. A negative aspect of our study was that we could not include a pruritus score, pruritus 
being a constant clinical sign in the evolution of sarcoptic mange in dog (Becskei et al., 2016; 
Beugnet et al., 2016; Romero et al., 2016; Taenzler et al., 2016; Hampel et al., 2018). 
As far as the treatment protocol is concerned, it included only one authorized molecule at 
that time for the treatment of sarcoptic mange in dogs, sarolaner. The reason why we did not choose 
this treatment for all animals and decided to use also doramectin was mainly because of economic 
reasons. Since most dogs were stray dogs, the persons taking care of them could only afford a 
limited sum of money for the treatment. As for the afoxolaner, we could offer some of the tablets 
for free. 
Contacting sarcoptic mange is influenced by predisposing factors, which are important for 





Firstly, we observed that age is the most recurrent variable that seems to group around 
young dogs. The percentage of dogs less than one year examined was 58.3%, which is similar to 
the findings published in other studies (Feather et al., 2010; Chen et al., 2014). 
The gender distribution had no particular value, since males represented 48% of the studied 
population and females slightly more with 52% of the population. This finding is consistent to 
other studies that state that sex was not a predisposing factor for contacting sarcoptic mange (Curtis 
and Paradis., 2003; Feather et al., 2010). 
Breed could not be interpreted in our study, since most dogs were common or crossbreeds. 
Regarding the source of contamination, we observed that contact with foxes could explain 
infection with S. scabiei mites, as we reported in the Boxer household, aspect observed also in 
2010 by Feather et al. 
On the frequency of the signs observed, alopecia, crusts and scales had the highest values, 
aspect that we also observed (Feather et. al., 2010; Becskei et al., 2016; Beugnet et al., 2016; 
Taenzler et al., 2016). 
Regarding the most affected body site of the dog, we found it was the head, especially the 
ears, which corresponds to the classic clinical signs which define the infection with S. scabiei 
(Kennis, 2004; Feather et al., 2010; Miller et al., 2012) 
In conclusion, our study supports the findings of previous research papers in the field, 
including predisposing factors of contacting mange, the source of contamination, and ads an 
original clinical score by evaluating the different characteristic signs that appear in mange, offering 
a general image of the situation of dogs with sarcoptic mange from Moldova region. 
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